BPI 2026 · Biotech

Genetix Biotherapeutics at BPI 2026

Somerville, Massachusetts

Genetix Biotherapeutics brings 4 presentations to BPI 2026 in Boston. Its sessions centre on planning cell and gene therapy manufacturing. One asks how to design facilities when the patient count keeps moving, and another argues for phase-appropriate manufacturing designed with the end in mind.

Organization

BPI 2026 Attendance

Genetix Biotherapeutics

Somerville, Massachusetts

1 Senior Director, Process Development · 1 VP of CMC Strategy & Ops

Biotech

Gene therapy company, formerly bluebird bio, with marketed lentiviral gene therapies for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy.

Chair

Thu Sep 24
9:20am–9:30am

Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics

Cell Therapy Manufacturing & Analytics

Talk

Thu Sep 24
11:45am–12:30pm

Designing for the Unknown: How Do You Plan CGT Manufacturing Facilities When the Patient Count is a Moving Target?

Development of Emerging Cell & Gene Therapies · with Hart Companies, Bristol Myers Squibb, Chrysalis

Talk

Thu Sep 24
4:30pm–5:30pm

Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development

Development of Emerging Cell & Gene Therapies · with Mill Creek Consulting, Ultragenyx, Astellas Institute for Regenerative Medicine